Business · 28/08/2024Updated: 10/17/2026 · 1 min read
FDA Awards Priority Review Voucher to Sponsor of Rare Pediatric Disease Product LIVMARLI
Summary
The FDA has issued a priority review voucher to Mirum Pharmaceuticals, Inc. for its rare pediatric disease product LIVMARLI (maralixibat), approved on September 29, 2021, following a review of the product against certain criteria.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →